Detalhe da pesquisa
1.
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants.
J Allergy Clin Immunol
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38763170
2.
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
Ann Neurol
; 93(1): 103-108, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36250739
3.
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Allergy
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38439527
4.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
J Neurol Neurosurg Psychiatry
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38548324
5.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
J Autoimmun
; 135: 102984, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621174
6.
SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(4): 280-283, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564175
7.
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
BMC Infect Dis
; 23(1): 332, 2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37198536
8.
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
BMC Med
; 20(1): 100, 2022 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236350
9.
Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection.
Front Immunol
; 15: 1314507, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38487524
10.
Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.
Front Neurol
; 13: 1032830, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36438945
11.
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.
Neurol Neuroimmunol Neuroinflamm
; 9(4)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35523569
12.
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273.
Elife
; 112022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35838348
13.
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Lancet Rheumatol
; 4(6): e417-e429, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35527808
14.
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.
Lancet Rheumatol
; 4(5): e338-e350, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35317410